<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01097902</url>
  </required_header>
  <id_info>
    <org_study_id>SU-03012010-5102</org_study_id>
    <nct_id>NCT01097902</nct_id>
  </id_info>
  <brief_title>Study of Experimental Models of Pain and Inflammation.</brief_title>
  <official_title>Experimental Inflammatory and Micro-incisional Pain Model Analysis by Gene Expression and Interstitial Fluid Proteomics of Skin Tissue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martin Angst</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      The experimental pain model studied in this proposal show characteristics of an inflamed
      wound with a pro-inflammatory response. This study will help discover candidate genetic
      and/or proteomic pain biomarkers that could provide objective and mechanism based tests to
      diagnose, monitor or quantify pain. We also hope to determine the measurable effects of a
      known non-steroidal anti-inflammatory drug (NSAID) on biomarkers of pain and inflammation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mechanical and thermal pain measurements, inflammatory COX and Prostaglandin E2 (PGE2) gene expression.</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interleukin-1beta and Interleukin-8 regulation</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Pain</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Ibuprophen 800 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral ibuprofen 800 mg, administered 24 hours after exposure to UV radiation for the creation of an inflamed lesion, and 2 hours prior to site evaluation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo administered 24 hours after exposure to UV radiation for the creation of an inflamed lesion, and 2 hours prior to site evaluation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>800 mg oral one time only</description>
    <arm_group_label>Ibuprophen 800 mg</arm_group_label>
    <other_name>Ibuprofen, generic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <description>Placebo tablet oral one time only</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:1) Age 18-60 2) Skin type II or III according to classification of
        Fitzpatrick 3) Negative pregnancy test (women of childbearing potential) 4) Willing and
        able to sign an informed consent form and Health Insurance Portability and Accountability
        Act (HIPAA) authorization and to comply with study procedures

        Exclusion Criteria:1) History of acute or chronic illness that may hinder study procedures
        or confuse interpretation of the data (e.g. dermatological, neurological, psychiatric or
        addictive diseases) 2) Clinically significant cardiovascular, pulmonary, hepatic or renal
        diseases 3) Major bodily injury within 3 months of study participation 4) Surgery within 3
        months of study participation 5) Pregnancy or breast-feeding 6) Intake of prescription
        drugs with anti/pro-inflammatory action 7) Intake of prescription drugs with
        anti/pro-analgesic action 8) Inability to abstain from any anti/pro inflammatory drugs
        during the 24-hour period preceding a study session 9) Inability to abstain from any
        anti/pro-analgesic drugs during the 24-hour period preceding a study session 10) Prior
        medical history that would contraindicate the use of NSAID, or previous negative reaction
        to NSAIDs or aspirin 11) Inability to obtain at least 6 hours of sleep during the night
        preceding a study session
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin S Angst</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Angst MS, Clark JD, Carvalho B, Tingle M, Schmelz M, Yeomans DC. Cytokine profile in human skin in response to experimental inflammation, noxious stimulation, and administration of a COX-inhibitor: a microdialysis study. Pain. 2008 Sep 30;139(1):15-27. doi: 10.1016/j.pain.2008.02.028. Epub 2008 Apr 8.</citation>
    <PMID>18396374</PMID>
  </reference>
  <reference>
    <citation>Angst MS, Tingle M, Schmelz M, Carvalho B, Yeomans DC. Human in-vivo bioassay for the tissue-specific measurement of nociceptive and inflammatory mediators. J Vis Exp. 2008 Dec 1;(22). pii: 1074. doi: 10.3791/1074.</citation>
    <PMID>19229167</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2010</study_first_submitted>
  <study_first_submitted_qc>April 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2010</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Martin Angst</investigator_full_name>
    <investigator_title>Professor of Anesthesia</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

